Drug interactions of macrolides: Emphasis on dirithromycin

Annals of Pharmacotherapy

Volumn 31, Issue 3, 1997, Pages 349-356

  Watkins, Vish S ^b   Polk, Ron E ^a   Stotka, Jennifer L ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; DIRITHROMYCIN; ERYTHROMYCIN; ETHINYLESTRADIOL; MACROLIDE; TERFENADINE; THEOPHYLLINE; WARFARIN;

AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; KIDNEY TRANSPLANTATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; VOLUNTEER;

EID: 0031042371     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100314     Document Type: Review

References (63)

1. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
2. Williams JD, Sefton AM. Comparison of macrolide antibiotics. J Antimicrob Chemother 1993;31(suppl C):11-26.
3. Barry AL, Pfaller MA, Fuchs PC. Dirithromycin disc susceptibility tests: interpretative criteria and quality control parameters. J Antimicrob Chemother 1993;31(suppl C):27-37.
4. Sides GD, Cerimele BJ, Black HR, Busch U, DeSante KA. Pharmacokinetics of dirithromycin. J Antimicrob Chemother 1993:31(suppl C):65-75.
5. Watkins PB. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990;10:235-50.
6. Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou J-P. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 1982;31:1699-1704.
7. Renton KW, Gray JD, Hung OR. Depression of theophylline elimination by erythromycin. Clin Pharmacol Ther 1981;30:422-6.
8. Prince RA, Wing DS, Weinberger MM, Hendeles LS, Riegelman S. Effect of erythromycin on theophylline kinetics. J Allergy Clin Immunol 1981;68:427-31.
9. Zarowitz BJM, Szefler SJ, Lasezkay GM. Effect of erythromycin base on theophylline kinetics. Clin Pharmacol Ther 1981;29:601-5.
10. Bukowskyj M, Nakatsu K, Munt PW. Theophylline reassessed. Ann Intern Med 1984;101:63-73.
11. Baciewicz AM, Baciewicz FA Jr. Cyclosporine pharmacokinetic drug interactions. Am J Surg 1989;157:264-71.
12. Lysz K, Rosenberg JC, Kaplan MP, Migdal S, Sillix D. Cyclosporine-drug interactions. Interaction of erythromycin with cyclosporine. Transplant Proc 1988;20(2, suppl 2):543-8.
13. Martell R, Heinrichs D, Stiller CR, Jenner M, Keown PA, Dupre J. The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 1986;104:660-1.
14. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984;144:2413-4.
15. Schwanz J, Bachmann K, Perrigo E, Interaction between warfarin and erythromycin. South Med J 1983;76:91-3.
16. Schwartz JI, Bachmann KA. Erythromycin-warfarin interaction (letter). Arch Intern Med 1984;144:2094.
17. Hassell D, Utt JK, Suspected interaction: warfarin and erythromycin. South Med J 1985;78:1015-6.
18. Husserl FE. Erythromycin-warfarin interaction. Arch Intern Med 1983;143:1831,1836.
19. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989;8:210-4.
20. Bachmann K, Schwartz JI, Forney R Jr, Frogameni A, Jauregui LE. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984;28:171-6.
21. Bachmann K. Screening for the influence of host factors on warfarin clearance using a single dose single sample procedure. Int J Clin Pharmacol Ther Toxicol 1986;24:167-70.
22. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992;26:46-55.
23. Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746-51.
24. Fisher D, Labbe G, Berson A, Tinel M, Loeper J, Larrey D, et al. Inhibition of rat liver estrogen 2/4-hydroxylase activity by troleandomycin: comparison with erythromycin and roxithromycin. J Pharmacol Exp Ther 1990;254:1120-7.
25. Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet J-P, Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 1994;58:725-7.
26. Gersema LM, Porter CB, Russell EH. Suspected drug interaction between cyclosporine and clarithromycin. J Heart Lung Transplant 1994;13:343-5.
27. Wolter K, Wagner K, Philipp T, Fritschka E. Interaction between FK 506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994;47:207-8.
28. Metz DC, Getz HD. Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. Dig Dis Sci 1995;40:912-5.
29. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993;34:161-2.
30. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-56.
31. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
32. Smith SJ. Cardiovascular toxicity of antihistamines. Otolaryngol Head Neck Surg 1994;111:348-54.
33. Nightingale SL. From the Food and Drug Administration. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992;268:705.
34. Saint-Salvi B, Tremblay D, Surjus A, Lefebvre MA. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother 1987;20 (suppl B):121-9.
35. Backman JT, Aranko K, Himberg J-J, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 1994;46:551-5.
36. Billaud EM, Guillemain R, Fortineau N, Kitzis M-D, Dreyfus G, Amrein C, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmcokinet 1990;19:499-502.
37. Paulsen O, Nilsson L-G, Saint-Salvi B, Manuel C, Lunell E. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol 1988;63:215-20.
38. Meyer B, Müller F, Wessels P, Maree J. A model to detect interactions between roxithromycin and oral contraceptives. Clin Pharmacol 1990;47:671-4.
39. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991;35:1186-90.
40. Kirst HA. Dirithromycin: its introduction and historical development. Drugs Today 1995;31(suppl C):1-10.
41. Counter FT, Ensminger PW, Preston DA, Wu C-YE, Greene JM, Felty-Duckworth AM, et al. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob Agents Chemother 1991;35:1116-26.
42. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1993;37:265-9.
43. Pershing LK, Franklin MR. Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. Xenobiotica 1982;12:687-99.
44. Baldit G, Vinçon G, Bistue C, Albin H. Influence of a new macrolide antibiotic, dirithromycin, on antipyrine clearance (in French). Therapie 1987;42:263-6.
45. Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, et al. The influence of dirithromycin on the pharmacokinetics of cyclo-sporine in healthy subjects and in renal transplant patients. Am J Ther 1995;2:490-8.
46. Shaw L. Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring. Clin Chem 1989;35:1299-308.
47. Kivistö K. A review of assay methods for cyclosporin. Clinical implications. Clin Pharmacokinet 1992;23:173-90.
48. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR, et al. Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987;23:776-8.
49. Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report (letter). Nephron 1995;70:130.
50. Ruff F, Chu S-Y, Sonders RC, Sennello LT. Effects of multiple doses of clarithromycin (C) on the pharmacokinetics (Pks) of theophylline (T) (abstract). In: Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Atlanta, GA.
51. Bachmann K, Jauregui L, Sides G, Sullivan TJ, Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol 1993;33:861-5.
52. Bachmann K, Nunlee M, Martin M, Sullivan T, Jauregui L, DeSante K, et al. Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin. J Clin Pharmacol 1990;30:1001-5.
53. Seldane, Seldane-D. In: Physicians' desk reference. 50th ed. Montvale, NJ: Medical Economics, 1996:1538-40.
54. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharm Ther 1995;58:310-5.
55. Goldberg MJ, DeSante K, Cerimele B, Sides G. Effect of dirithromycin on terfenadine pharmacokinetics and QTc in healthy men (abstract). Presented at the 96th annual meeting of the American Society for Clinical Pharmacology and Therapeutics, March 15-17, 1995, San Diego, CA.
56. Ellsworth A, Horn JR, Wilkinson W, Black DJ, Church L. An evaluation of the effect of dirithromycin (D) and erythromycin (E) on the pharmacokinetics and pharmacodynamics of warfarin (W) (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
57. Fleischer AB Jr, Resnick SD, The effect of antibiotics on the efficacy of oral contraceptives. A controversy revisited. Arch Dermatol 1989;125:1562-4.
58. Back DJ, Grimmer SFM, Orme ML'E, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988;25:527-32.
59. Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril 1988;49(suppl):31S-8S.
60. Fotherby K. Interactions with oral contraceptives. Am J Obstet Gynecol 1990;163:2153-9.
61. Back DJ, Orme ML'E. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-84.
62. Wermeling DP, Chandler MHH, Sides GD, Collins D, Muse KN. Dirithromycin increases ethinyl estradiol clearance without allowing ovulation. Obstet Gynecol 1995;86:78-84.
63. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids. An update. Clin Pharmacokinet 1991;20:15-37.